市場調查報告書

滲出型老齡化黃斑部病變 (AMD)的全球市場:規模、佔有率、發展、成長率、需求預測

Wet Age-Related Macular Degeneration Market by Product, by Distribution Channel, by Age Group, by Route of Administration, by End User, by Geography Global Market Size, Share, Development, Growth, and Demand Forecast, 20142024

出版商 Prescient & Strategic Intelligence Private Limited 商品編碼 839555
出版日期 內容資訊 英文 175 Pages
商品交期: 2-3個工作天內
價格
Back to Top
滲出型老齡化黃斑部病變 (AMD)的全球市場:規模、佔有率、發展、成長率、需求預測 Wet Age-Related Macular Degeneration Market by Product, by Distribution Channel, by Age Group, by Route of Administration, by End User, by Geography Global Market Size, Share, Development, Growth, and Demand Forecast, 20142024
出版日期: 2019年03月01日內容資訊: 英文 175 Pages
簡介

本報告提供滲出型老齡化黃斑部病變 (AMD)的世界市場調查,市場概要,各市場區隔、各地區的市場規模的變化與預測,市場成長要素及阻礙因素分析,市場機會,競爭情形,主要企業的簡介等,全面性資訊。

第1章 調查背景

第2章 調查手法

第3章 摘要整理

第4章 簡介

  • 市場區隔定義
    • 各產品
    • 各流通管道
    • 各年齡層
    • 各給藥途徑
    • 各終端用戶
  • 市場動態
    • 趨勢
    • 促進因素
    • 阻礙因素
    • 機會
  • 波特的五力分析
  • 流行病學概要
  • 滲出型AMD的開發平台藥物
  • 藥價、醫療費償付情形

第5章 世界市場規模、預測

  • 各產品
  • 各流通管道
  • 各年齡層
  • 各給藥途徑
  • 各終端用戶
  • 各地區

第6章 北美市場規模、預測

  • 各產品
  • 各流通管道
  • 各年齡層
  • 各給藥途徑
  • 各終端用戶
  • 各國

第7章 歐洲市場規模、預測

第8章 亞太地區市場規模、預測

第9章 南美市場規模、預測

第10章 中東、非洲市場規模、預測

第11章 全球策略開發

  • 臨床試驗的認證、結果
  • 收購、合作

第12章 企業簡介

  • Regeneron Pharmaceuticals Inc.
  • Neurotech Pharmaceuticals Inc.
  • Ophthotech Corporation
  • 窪田製藥集團
  • Alimera Sciences Inc.
  • Adverum Biotechnologies Inc.
  • Gilead Sciences Inc.
  • Apellis Pharmeceuticals Inc.
  • Novartis AG
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • Allergan plc
  • Bausch Health Companies Inc.

第13章 附錄

目錄

According to P&S Intelligence, the global wet age-related macular degeneration (AMD) market attained a size of $6.9 billion in 2018, and it is expected to reach $10.4 billion by 2024, advancing at a CAGR of 7.1% during the forecast period (2019-2024). The growth of the market is driven by the rising prevalence of AMD, lack of a specific treatment, and increasing aging population.

Eylea, Lucentis, and Avastin are the drugs available worldwide for the treatment of wet AMD. Out of these, Eylea is anticipated to dominate the market in 2019-2024. The major factors escalating the demand for this drug in the global wet age-related macular degeneration market are the rising prevalence of AMD.

On the basis of route of administration, the market is bifurcated into intravenously and intravitreally given drugs. During the forecast period, the drugs administered through the intravitreal route are predicted to witness the faster growth at a CAGR of 7.2% in the global wet age-related macular degeneration market.

In 2018, North America held the largest revenue share, amounting to nearly $3.0 billion, in the global wet age-related macular degeneration market. This is ascribed to the increasing prevalence of wet AMD, rising number of drug approvals, and considerable presence of key players in the country.

On a global ground, during the 2019-2024 period, the market is projected to observe the fastest growth with a CAGR of 8.8% in APAC, owing to the surge in the aging population, increase in the prevalence of AMD, and reimbursements offered by the government for treating wet age-related macular degradation in the region.

Furthermore, APAC accounts for over one-third of the macular degeneration cases registered across the globe, which is anticipated to further rise during the forecast period. According to United Nations projections, nearly 24.0% of Asians will be of 60 years or above by 2050. Since aged people are more likely to develop AMD, the demand for medication for disease treatment is predicted to substantially rise in the region, resulting in the growth of the wet age-related macular degeneration market.

Also, wet AMD treatment is quite expensive, as a result of which the government of countries such as South Korea and Malaysia have introduced some health insurance plans to cover the cost of the treatment to some extent and to lessen the burden of healthcare on people. For instance, under the universal government health insurance plan of South Korea's, during their lifetime, wet AMD patients can get up to 10 injections of ranibizumab. Thus, the increasing government initiatives are boosting the wet age-related macular degeneration market growth in the APAC region.

WET AGE-RELATED MACULAR DEGENERATION MARKET SEGMENTATION

Market Segmentation by Product

  • Lucentis
  • Eylea
  • Avastin
  • Others

Market Segmentation by Distribution Channel

  • Direct
  • Indirect

Market Segmentation by Age Group

  • Above 80 Years
  • 60-80 Years
  • 40-59 Years

Market Segmentation by Route of Administration

  • Intravitreal
  • Intravenous

Market Segmentation by End User

  • Hospitals and Clinics
  • Research and Academic Institute

Market Segmentation by Geography

North America Wet AMD Market

  • By product
  • By distribution channel
  • By age group
  • By route of administration
  • By end user
  • By country - U.S. and Canada

Europe Wet AMD Market

  • By product
  • By distribution channel
  • By age group
  • By route of administration
  • By end user
  • By country - Germany, U.K., France, Italy, Spain, Russia, Sweden, Norway, Belgium, Switzerland, Austria, and Rest of Europe

Asia-Pacific (APAC) Wet AMD Market

  • By product
  • By distribution channel
  • By age group
  • By route of administration
  • By end user
  • By country - Japan, China, India, Australia, Singapore, South Korea, Malaysia, Thailand, and Rest of APAC

Latin America (LATAM) Wet AMD Market

  • By product
  • By distribution channel
  • By age group
  • By route of administration
  • By end user
  • By country - Brazil, Mexico, Argentina, Colombia, and Rest of LATAM

Middle East and Africa (MEA) Wet AMD Market

  • By product
  • By distribution channel
  • By age group
  • By route of administration
  • By end user
  • By country - Israel, South Africa, Saudi Arabia, and Rest of MEA

Table of Content

Chapter 1. Research Background

  • 1.1 Research Objectives
  • 1.2 Market Definition
  • 1.3 Research Scope
    • 1.3.1 Market Segmentation by Product
    • 1.3.2 Market Segmentation by Distribution Channel
    • 1.3.3 Market Segmentation by Age Group
    • 1.3.4 Market Segmentation by Route of Administration
    • 1.3.5 Market Segmentation by End User
    • 1.3.6 Market Segmentation by Geography
    • 1.3.7 Analysis Period
    • 1.3.8 Market Data Reporting Unit
      • 1.3.8.1 Value
  • 1.4 Key Stakeholders

Chapter 2. Research Methodology

  • 2.1 Secondary Research
  • 2.2 Primary Research
    • 2.2.1 Breakdown of Primary Research Respondents
      • 2.2.1.1 By region
      • 2.2.1.2 By industry participant
      • 2.2.1.3 By company type
  • 2.3 Market Size Estimation
  • 2.4 Data Triangulation
  • 2.5 Assumptions for the Study

Chapter 3. Executive Summary

Chapter 4. Introduction

  • 4.1 Definition of Market Segments
    • 4.1.1 By Product
      • 4.1.1.1 Lucentis
      • 4.1.1.2 Eylea
      • 4.1.1.3 Avastin
      • 4.1.1.4 Others
    • 4.1.2 By Distribution Channel
      • 4.1.2.1 Direct
      • 4.1.2.2 Indirect
    • 4.1.3 By Age Group
      • 4.1.3.1 Above 80 years
        • 4.1.3.2 60-80 years
        • 4.1.3.3 40-59 years
    • 4.1.4 By Route of Administration
      • 4.1.4.1 Intravitreal
      • 4.1.4.2 Intravenous
    • 4.1.5 By End User
      • 4.1.5.1 Hospitals and clinics
      • 4.1.5.2 Research and academic institutes
  • 4.2 Market Dynamics
    • 4.2.1 Trends
      • 4.2.1.1 Positive clinical trial results and increasing approvals for pipeline drugs
      • 4.2.1.2 Growing number of acquisitions and collaborations
    • 4.2.2 Drivers
      • 4.2.2.1 Increasing prevalence of AMD
      • 4.2.2.2 Lack of availability of specific treatment
      • 4.2.2.3 Surge in geriatric population
      • 4.2.2.4 Impact analysis of drivers on market forecast
    • 4.2.3 Restraints
      • 4.2.3.1 Increasing usage of off-label drugs
      • 4.2.3.2 High cost of drugs and lack of insurance coverage
      • 4.2.3.3 Impact analysis of restraints on market forecast
    • 4.2.4 Opportunities
      • 4.2.4.1 Emerging market for wet AMD in APAC
      • 4.2.4.2 Prospective alternative therapies
  • 4.3 Porter's Five Forces Analysis
  • 4.4 Epidemiology Overview
  • 4.5 Pipeline Drugs for Wet AMD
  • 4.6 Pricing and Reimbursement Scenario
    • 4.6.1 Pricing
    • 4.6.2 Reimbursement

Chapter 5. Global Market Size and Forecast

  • 5.1 By Product
  • 5.2 By Distribution Channel
  • 5.3 By Age Group
  • 5.4 By Route of Administration
  • 5.5 By End User
  • 5.6 By Region

Chapter 6. North America Market Size and Forecast

  • 6.1 By Product
  • 6.2 By Distribution Channel
  • 6.3 By Age Group
  • 6.4 By Route of Administration
  • 6.5 By End User
  • 6.6 By Country

Chapter 7. Europe Market Size and Forecast

  • 7.1 By Product
  • 7.2 By Distribution Channel
  • 7.3 By Age Group
  • 7.4 By Route of Administration
  • 7.5 By End User
  • 7.6 By Country

Chapter 8. APAC Market Size and Forecast

  • 8.1 By Product
  • 8.2 By Distribution Channel
  • 8.3 By Age Group
  • 8.4 By Route of Administration
  • 8.5 By End User
  • 8.6 By Country

Chapter 9. LATAM Market Size and Forecast

  • 9.1 By Product
  • 9.2 By Distribution Channel
  • 9.3 By Age Group
  • 9.4 By Route of Administration
  • 9.5 By End User
  • 9.6 By Country

Chapter 10. MEA Market Size and Forecast

  • 10.1 By Product
  • 10.2 By Distribution Channel
  • 10.3 By Age Group
  • 10.4 By Route of Administration
  • 10.5 By End User
  • 10.6 By Country

Chapter 11. Global Strategic Developments

  • 11.1 Clinical Trial Approvals and Results
  • 11.2 Acquisitions and Collaborations

Chapter 12. Company Profiles

  • 12.1 Regeneron Pharmaceuticals Inc.
    • 12.1.1 Business Overview
    • 12.1.2 Product and Service Offerings
    • 12.1.3 Key Financial Summary
    • 12.1.4 SWOT Analysis
  • 12.2 Neurotech Pharmaceuticals Inc.
    • 12.2.1 Business Overview
    • 12.2.2 Product and Service Offerings
  • 12.3 Ophthotech Corporation
    • 12.3.1 Business Overview
    • 12.3.2 Product and Service Offerings
    • 12.3.3 Key Financial Summary
  • 12.4 Kubota Pharmaceutical Holdings Co. Ltd.
    • 12.4.1 Business Overview
    • 12.4.2 Product and Service Offerings
    • 12.4.3 Key Financial Summary
  • 12.5 Alimera Sciences Inc.
    • 12.5.1 Business Overview
    • 12.5.2 Product and Service Offerings
    • 12.5.3 Key Financial Summary
    • 12.5.4 SWOT Analysis
  • 12.6 Adverum Biotechnologies Inc.
    • 12.6.1 Business Overview
    • 12.6.2 Product and Service Offerings
  • 12.7 Gilead Sciences Inc.
    • 12.7.1 Business Overview
    • 12.7.2 Product and Service Offerings
      • 12.7.2.1 Marketed products
      • 12.7.2.2 Pipeline products
    • 12.7.3 Key Financial Summary
    • 12.7.4 SWOT Analysis
  • 12.8 Apellis Pharmeceuticals Inc.
    • 12.8.1 Business Overview
    • 12.8.2 Product and Service Offerings
  • 12.9 Novartis AG
    • 12.9.1 Business Overview
    • 12.9.2 Product and Service Offerings
      • 12.9.2.1 Marketed products
      • 12.9.2.2 Pipeline products
    • 12.9.3 Key Financial Summary
  • 12.10 Pfizer Inc.
    • 12.10.1 Business Overview
    • 12.10.2 Product and Service Offerings
      • 12.10.2.1 Marketed products
      • 12.10.2.2 Pipeline products
    • 12.10.3 Key Financial Summary
  • 12.11 GlaxoSmithKline plc
    • 12.11.1 Business Overview
    • 12.11.2 Product and Service Offerings
      • 12.11.2.1 Marketed products
      • 12.11.2.2 Pipeline products
    • 12.11.3 Key Financial Summary
  • 12.12 Bayer AG
    • 12.12.1 Business Overview
    • 12.12.2 Product and Service Offerings
    • 12.12.3 Key Financial Summary
  • 12.13 F. Hoffmann-La Roche Ltd.
    • 12.13.1 Business Overview
    • 12.13.2 Product and Service Offerings
    • 12.13.3 Key Financial Summary
  • 12.14 Allergan plc
    • 12.14.1 Business Overview
    • 12.14.2 Product and Service Offerings
    • 12.14.3 Key Financial Summary
  • 12.15 Bausch Health Companies Inc.
    • 12.15.1 Business Overview
    • 12.15.2 Product and Service Offerings
    • 12.15.3 Key Financial Summary

Chapter 13. Appendix

  • 13.1 Abbreviations
  • 13.2 Sources and References
  • 13.3 Related Reports

List of Tables

  • TABLE 1 ANALYSIS PERIOD OF THE STUDY
  • TABLE 2 DRIVERS FOR THE MARKET: IMPACT ANALYSIS
  • TABLE 3 RESTRAINTS FOR THE MARKET: IMPACT ANALYSIS
  • TABLE 4 LIST OF PHASE III DRUGS
  • TABLE 5 LIST OF PHASE II DRUGS
  • TABLE 6 LIST OF PHASE I DRUGS
  • TABLE 7 LIST OF PRE-CLINICAL DRUGS
  • TABLE 8 COST COMPARISON OF ANTI-VEGF THERAPIES FOR MCNV
  • TABLE 9 REIMBURSEMENT RATES OF LUCENTIS AND EYLEA PER UNIT DOSE
  • TABLE 10 GLOBAL WET AMD MARKET, BY PRODUCT, $M (2014-2018)
  • TABLE 11 GLOBAL WET AMD MARKET, BY PRODUCT, $M (2019-2024)
  • TABLE 12 GLOBAL WET AMD MARKET, BY DISTRIBUTION CHANNEL, $M (2014-2018)
  • TABLE 13 GLOBAL WET AMD MARKET, BY DISTRIBUTION CHANNEL, $M (2019-2024)
  • TABLE 14 GLOBAL WET AMD MARKET, BY AGE GROUP, $M (2014-2018)
  • TABLE 15 GLOBAL WET AMD MARKET, BY AGE GROUP, $M (2019-2024)
  • TABLE 16 GLOBAL WET AMD MARKET, BY ROUTE OF ADMINISTRATION, $M (2014-2018)
  • TABLE 17 GLOBAL WET AMD MARKET, BY ROUTE OF ADMINISTRATION, $M (2019-2024)
  • TABLE 18 GLOBAL WET AMD MARKET, BY END USER, $M (2014-2018)
  • TABLE 19 GLOBAL WET AMD MARKET, BY END USER, $M (2019-2024)
  • TABLE 20 GLOBAL WET AMD MARKET, BY REGION, $M (2014-2018)
  • TABLE 21 GLOBAL WET AMD MARKET, BY REGION, $M (2019-2024)
  • TABLE 22 NORTH AMERICA WET AMD MARKET, BY PRODUCT, $M (2014-2018)
  • TABLE 23 NORTH AMERICA WET AMD MARKET, BY PRODUCT, $M (2019-2024)
  • TABLE 24 NORTH AMERICA WET AMD MARKET, BY DISTRIBUTION CHANNEL, $M (2014-2018)
  • TABLE 25 NORTH AMERICA WET AMD MARKET, BY DISTRIBUTION CHANNEL, $M (2019-2024)
  • TABLE 26 NORTH AMERICA WET AMD MARKET, BY AGE GROUP, $M (2014-2018)
  • TABLE 27 NORTH AMERICA WET AMD MARKET, BY AGE GROUP, $M (2019-2024)
  • TABLE 28 NORTH AMERICA WET AMD MARKET, BY ROUTE OF ADMINISTRATION, $M (2014-2018)
  • TABLE 29 NORTH AMERICA WET AMD MARKET, BY ROUTE OF ADMINISTRATION, $M (2019-2024)
  • TABLE 30 NORTH AMERICA WET AMD MARKET, BY END USER, $M (2014-2018)
  • TABLE 31 NORTH AMERICA WET AMD MARKET, BY END USER, $M (2019-2024)
  • TABLE 32 NORTH AMERICA WET AMD MARKET, BY COUNTRY, $M (2014-2018)
  • TABLE 33 NORTH AMERICA WET AMD MARKET, BY COUNTRY, $M (2019-2024)
  • TABLE 34 EUROPE WET AMD MARKET, BY PRODUCT, $M (2014-2018)
  • TABLE 35 EUROPE WET AMD MARKET, BY PRODUCT, $M (2019-2024)
  • TABLE 36 EUROPE WET AMD MARKET, BY DISTRIBUTION CHANNEL, $M (2014-2018)
  • TABLE 37 EUROPE WET AMD MARKET, BY DISTRIBUTION CHANNEL, $M (2019-2024)
  • TABLE 38 EUROPE WET AMD MARKET, BY AGE GROUP, $M (2014-2018)
  • TABLE 39 EUROPE WET AMD MARKET, BY AGE GROUP, $M (2019-2024)
  • TABLE 40 EUROPE WET AMD MARKET, BY ROUTE OF ADMINISTRATION, $M (2014-2018)
  • TABLE 41 EUROPE WET AMD MARKET, BY ROUTE OF ADMINISTRATION, $M (2019-2024)
  • TABLE 42 EUROPE WET AMD MARKET, BY END USER, $M (2014-2018)
  • TABLE 43 EUROPE WET AMD MARKET, BY END USER, $M (2019-2024)
  • TABLE 44 EUROPE WET AMD MARKET, BY COUNTRY, $M (2014-2018)
  • TABLE 45 EUROPE WET AMD MARKET, BY COUNTRY, $M (2019-2024)
  • TABLE 46 APAC WET AMD MARKET, BY PRODUCT, $M (2014-2018)
  • TABLE 47 APAC WET AMD MARKET, BY PRODUCT, $M (2019-2024)
  • TABLE 48 APAC WET AMD MARKET, BY DISTRIBUTION CHANNEL, $M (2014-2018)
  • TABLE 49 APAC WET AMD MARKET, BY DISTRIBUTION CHANNEL, $M (2019-2024)
  • TABLE 50 APAC WET AMD MARKET, BY AGE GROUP, $M (2014-2018)
  • TABLE 51 APAC WET AMD MARKET, BY AGE GROUP, $M (2019-2024)
  • TABLE 52 APAC WET AMD MARKET, BY ROUTE OF ADMINISTRATION, $M (2014-2018)
  • TABLE 53 APAC WET AMD MARKET, BY ROUTE OF ADMINISTRATION, $M (2019-2024)
  • TABLE 54 APAC WET AMD MARKET, BY END USER, $M (2014-2018)
  • TABLE 55 APAC WET AMD MARKET, BY END USER, $M (2019-2024)
  • TABLE 56 APAC WET AMD MARKET, BY COUNTRY, $M (2014-2018)
  • TABLE 57 APAC WET AMD MARKET, BY COUNTRY, $M (2019-2024)
  • TABLE 58 LATAM WET AMD MARKET, BY PRODUCT, $M (2014-2018)
  • TABLE 59 LATAM WET AMD MARKET, BY PRODUCT, $M (2019-2024)
  • TABLE 60 LATAM WET AMD MARKET, BY DISTRIBUTION CHANNEL, $M (2014-2018)
  • TABLE 61 LATAM WET AMD MARKET, BY DISTRIBUTION CHANNEL, $M (2019-2024)
  • TABLE 62 LATAM WET AMD MARKET, BY AGE GROUP, $M (2014-2018)
  • TABLE 63 LATAM WET AMD MARKET, BY AGE GROUP, $M (2019-2024)
  • TABLE 64 LATAM WET AMD MARKET, BY ROUTE OF ADMINISTRATION, $M (2014-2018)
  • TABLE 65 LATAM WET AMD MARKET, BY ROUTE OF ADMINISTRATION, $M (2019-2024)
  • TABLE 66 LATAM WET AMD MARKET, BY END USER, $M (2014-2018)
  • TABLE 67 LATAM WET AMD MARKET, BY END USER, $M (2019-2024)
  • TABLE 68 LATAM WET AMD MARKET, BY COUNTRY, $M (2014-2018)
  • TABLE 69 LATAM WET AMD MARKET, BY COUNTRY, $M (2019-2024)
  • TABLE 70 MEA WET AMD MARKET, BY PRODUCT, $M (2014-2018)
  • TABLE 71 MEA WET AMD MARKET, BY PRODUCT, $M (2019-2024)
  • TABLE 72 MEA WET AMD MARKET, BY DISTRIBUTION CHANNEL, $M (2014-2018)
  • TABLE 73 MEA WET AMD MARKET, BY DISTRIBUTION CHANNEL, $M (2019-2024)
  • TABLE 74 MEA WET AMD MARKET, BY AGE GROUP, $M (2014-2018)
  • TABLE 75 MEA WET AMD MARKET, BY AGE GROUP, $M (2019-2024)
  • TABLE 76 MEA WET AMD MARKET, BY ROUTE OF ADMINISTRATION, $M (2014-2018)
  • TABLE 77 MEA WET AMD MARKET, BY ROUTE OF ADMINISTRATION, $M (2019-2024)
  • TABLE 78 MEA WET AMD MARKET, BY END USER, $M (2014-2018)
  • TABLE 79 MEA WET AMD MARKET, BY END USER, $M (2019-2024)
  • TABLE 80 MEA WET AMD MARKET, BY COUNTRY, $M (2014-2018)
  • TABLE 81 MEA WET AMD MARKET, BY COUNTRY, $M (2019-2024)
  • TABLE 82 REGENERON PHARMACEUTICALS INC. - AT A GLANCE
  • TABLE 83 REGENERON PHARMACEUTICALS INC. - KEY FINANCIAL SUMMARY
  • TABLE 84 NEUROTECH PHARMACEUTICALS INC. - AT A GLANCE
  • TABLE 86 OPHTHOTECH CORPORTION - KEY FINANCIAL SUMMARY
  • TABLE 88 KUBOTA PHARMACEUTICAL HOLDINGS CO. LTD. - KEY FINANCIAL SUMMARY
  • TABLE 90 ALIMERA SCIENCES INC. - KEY FINANCIAL SUMMARY
  • TABLE 92 GILEAD SCIENCES INC. - AT A GLANCE
  • TABLE 93 GILEAD SCIENCES INC. - KEY FINANCIAL SUMMARY
  • TABLE 95 NOVARTIS AG - AT A GLANCE
  • TABLE 96 NOVARTIS AG - KEY FINANCIAL SUMMARY
  • TABLE 97 PFIZER INC. - AT A GLANCE
  • TABLE 98 PFIZER INC. - KEY FINANCIAL SUMMARY
  • TABLE 99 GLAXOSMITHKLINE PLC - AT A GLANCE
  • TABLE 100 GLAXOSMITHKLINE PLC - KEY FINANCIAL SUMMARY
  • TABLE 101 BAYER AG - AT A GLANCE
  • TABLE 102 BAYER AG - KEY FINANCIAL SUMMARY
  • TABLE 103 F. HOFFMANN-LA ROCHE LTD. - AT A GLANCE
  • TABLE 104 PRODUCT UNDER DEVELOPMENT
  • TABLE 105 F. HOFFMANN-LA ROCHE LTD. - KEY FINANCIAL SUMMARY
  • TABLE 106 ALLERGAN PLC - AT A GLANCE
  • TABLE 107 ALLERGAN PLC - KEY FINANCIAL SUMMARY
  • TABLE 108 BAUSCH HEALTH COMPANIES INC. - AT A GLANCE
  • TABLE 109 BAUSCH HEALTH COMPANIES INC. - KEY FINANCIAL SUMMARY

List of Figures

  • FIG 1 RESEARCH SCOPE
  • FIG 2 RESEARCH METHODOLOGY
  • FIG 3 REGIONAL SPLIT OF PRIMARY AND SECONDARY RESEARCH
  • FIG 4 BREAKDOWN OF PRIMARY RESEARCH BY REGION
  • FIG 5 BREAKDOWN OF PRIMARY RESEARCH BY INDUSTRY PARTICIPANT
  • FIG 6 BREAKDOWN OF PRIMARY RESEARCH BY COMPANY TYPE
  • FIG 7 DATA TRIANGULATION APPROACH
  • FIG 8 GLOBAL WET AMD MARKET SUMMARY
  • FIG 9 BARGAINING POWER OF BUYERS
  • FIG 10 BARGAINING POWER OF SUPPLIERS
  • FIG 11 INTENSITY OF RIVALRY
  • FIG 12 THREAT OF NEW ENTRANTS
  • FIG 13 THREAT OF SUBSTITUTES
  • FIG 14 SNAPSHOT OF GLOBAL WET AMD MARKET (2018)
  • FIG 15 GLOBAL WET AMD MARKET, BY PRODUCT, $M (2014-2024)
  • FIG 16 GLOBAL WET AMD MARKET, BY DISTRIBUTION CHANNEL, $M (2014-2024)
  • FIG 17 GLOBAL WET AMD MARKET, BY AGE GROUP, $M (2014-2024)
  • FIG 18 GLOBAL WET AMD MARKET, BY ROUTE OF ADMINISTRATION, $M (2014-2024)
  • FIG 19 GLOBAL WET AMD MARKET, BY END USER, $M (2014-2024)
  • FIG 20 MAJOR MARKETS FOR WET AMD DRUGS
  • FIG 21 NORTH AMERICA WET AMD MARKET SNAPSHOT
  • FIG 22 NORTH AMERICA WET AMD MARKET, BY PRODUCT, $M (2014-2024)
  • FIG 23 NORTH AMERICA WET AMD MARKET, BY DISTRIBUTION CHANNEL, $M (2014-2024)
  • FIG 24 NORTH AMERICA WET AMD MARKET, BY AGE GROUP, $M (2014-2024)
  • FIG 25 NORTH AMERICA WET AMD MARKET, BY ROUTE OF ADMINISTRATION, $M (2014-2024)
  • FIG 26 NORTH AMERICA WET AMD MARKET, BY END USER, $M (2014-2024)
  • FIG 27 NORTH AMERICA WET AMD MARKET, BY COUNTRY, $M (2014-2024)
  • FIG 28 EUROPE WET AMD MARKET SNAPSHOT
  • FIG 29 EUROPE WET AMD MARKET, BY PRODUCT, $M (2014-2024)
  • FIG 30 EUROPE WET AMD MARKET, BY DISTRIBUTION CHANNEL, $M (2014-2024)
  • FIG 31 EUROPE WET AMD MARKET, BY AGE GROUP, $M (2014-2024)
  • FIG 32 EUROPE WET AMD MARKET, BY ROUTE OF ADMINISTRATION, $M (2014-2024)
  • FIG 33 EUROPE WET AMD MARKET, BY END USER, $M (2014-2024)
  • FIG 34 EUROPE WET AMD MARKET, BY COUNTRY, $M (2014-2024)
  • FIG 35 APAC WET AMD MARKET SNAPSHOT
  • FIG 36 APAC WET AMD MARKET, BY PRODUCT, $M (2014-2024)
  • FIG 37 APAC WET AMD MARKET, BY DISTRIBUTION CHANNEL, $M (2014-2024)
  • FIG 38 APAC WET AMD MARKET, BY AGE GROUP, $M (2014-2024)
  • FIG 39 APAC WET AMD MARKET, BY ROUTE OF ADMINISTRATION, $M (2014-2024)
  • FIG 40 APAC WET AMD MARKET, BY END USER, $M (2014-2024)
  • FIG 41 APAC WET AMD MARKET, BY COUNTRY, $M (2014-2024)
  • FIG 42 LATAM WET AMD MARKET SNAPSHOT
  • FIG 43 LATAM WET AMD MARKET, BY PRODUCT, $M (2014-2024)
  • FIG 44 LATAM WET AMD MARKET, BY DISTRIBUTION CHANNEL, $M (2014-2024)
  • FIG 45 LATAM WET AMD MARKET, BY AGE GROUP, $M (2014-2024)
  • FIG 46 LATAM WET AMD MARKET, BY ROUTE OF ADMINISTRATION, $M (2014-2024)
  • FIG 47 LATAM WET AMD MARKET, BY END USER, $M (2014-2024)
  • FIG 48 LATAM WET AMD MARKET, BY COUNTRY, $M (2014-2024)
  • FIG 49 MEA WET AMD MARKET SNAPSHOT
  • FIG 50 MEA WET AMD MARKET, BY PRODUCT, $M (2014-2024)
  • FIG 51 MEA WET AMD MARKET, BY DISTRIBUTION CHANNEL, $M (2014-2024)
  • FIG 52 MEA WET AMD MARKET, BY AGE GROUP, $M (2014-2024)
  • FIG 53 MEA WET AMD MARKET, BY ROUTE OF ADMINISTRATION, $M (2014-2024)
  • FIG 54 MEA WET AMD MARKET, BY END USER, $M (2014-2024)
  • FIG 55 MEA WET AMD MARKET, BY COUNTRY, $M (2014-2024)
  • FIG 56 REGENERON PHARMACEUTICALS INC. - REVENUE SPLIT BY MARKETED PRODUCT (2018)
  • FIG 57 ALIMERA SCIENCES INC. - REVENUE SPLIT BY GEOGRAPHY (2017)
  • FIG 58 GILEAD SCIENCES INC. - REVENUE SPLIT BY PRODUCT SALES AND GEOGRAPHY (2017)
  • FIG 59 NOVARTIS AG - REVENUE SPLIT BY MARKETED PRODUCT AND GEOGRAPHY (2017)
  • FIG 60 PFIZER INC. - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2017)
  • FIG 61 GLAXOSMITHKLINE PLC - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2017)
  • FIG 62 BAYER AG - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2017)
  • FIG 63 F. HOFFMANN-LA ROCHE LTD. - REVENUE SPLIT BY DIVISION AND GEOGRAPHY (2017)
  • FIG 64 ALLERGAN PLC - REVENUE SPLIT BY SEGMENT (2017)
  • FIG 65 BAUSCH HEALTH COMPANIES INC. - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2017)
Back to Top